Title
Category
Credits
Event date
Cost
  • Alzheimer Disease
  • Dementia
  • Neuroimaging
  • Primary Care
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
Early-stage diagnosis of Alzheimer disease leads to prompt treatment initiation and better patient QoL. Learn about new guidelines and technology advances and what’s on the horizon from authorities in the field.
  • Alzheimer Disease
  • Dementia
  • Integrated Care
  • Neuroimaging
  • Patient/Physician Communication
  • Primary Care
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
Prompt treatment of early-stage Alzheimer disease (AD) can curb symptom progression. Tests for biomarkers, new symptomatic treatments and disease-modifying agents, and the addition of the preclinical stage to AD diagnostic criteria can aid in earlier disease recognition and building treatment plans.
  • Alzheimer Disease
  • Dementia
  • Integrated Care
  • Neuroimaging
  • Patient/Physician Communication
  • Primary Care
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
Many new therapies for early-stage AD have made their way onto the scene that can delay onset of the disease and/or slow down progression. Find out the how, what, when to better treat your patients with AD from specialists in the field.
  • Alzheimer Disease
  • Dementia
  • Diagnostic Tools
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
Great strides in research on Alzheimer disease diagnostic biomarkers and treatment targets have taken place over the past 2 decades. Listen as Dr Goldfarb highlights exciting developments.

Pages